Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Stefano Paolucci. (2017) Advances in antidepressants for treating post-stroke depression. Expert Opinion on Pharmacotherapy 18:10, pages 1011-1017.
Read now
Read now
Alonso Montoya, Robert Bruins, Martin A Katzman & Pierre Blier. (2016) The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatric Disease and Treatment 12, pages 541-557.
Read now
Read now
Zheng-Yi Zhou, Shawn Sun, Pooja Chopra, Yichen Zhong, Todor Totev & James Signorovitch. (2015) Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Journal of Medical Economics 18:11, pages 919-929.
Read now
Read now
Articles from other publishers (32)
Shuzhe Zhou, Pei Li, Xiaozhen Lv, Xuefeng Lai, Zuoxiang Liu, Junwen Zhou, Fengqi Liu, Yiming Tao, Meng Zhang, Xin Yu, Jingwei Tian & Feng Sun. (2023) Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. SLEEP.
Crossref
Crossref
Weifeng Mi, Xiaolan Di, Yiming Wang, Huafang Li, Xiufeng Xu, Lehua Li, Huaning Wang, Guoqiang Wang, Kerang Zhang, Feng Tian, Jiong Luo, Chanjuan Yang, Yunfei Zhou, Shiping Xie, Hua Zhong, Bin Wu, Dong Yang, Zhenhua Chen, Yi Li, Jindong Chen, Shuyun Lv, Qizhong Yi, Zhiwei Jiang, Jingwei Tian & Hongyan Zhang. (2023) A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder. Translational Psychiatry 13:1.
Crossref
Crossref
Joseph F. Goldberg, Michael Q. Steinman & Stephen M. Stahl. (2023) Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability. Neuroscience Applied 2, pages 101127.
Crossref
Crossref
Weifeng Mi, Fude Yang, Huafang Li, Xiufeng Xu, Lehua Li, Qingrong Tan, Guoqiang Wang, Kerang Zhang, Feng Tian, Jiong Luo, Jielai Xia, Kai Yuan, Lin Lu, Jiahui Deng, Jingwei Tian & Hongyan Zhang. (2022) Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial. International Journal of Neuropsychopharmacology 25:3, pages 252-260.
Crossref
Crossref
Rabie Karrouri, Zakaria Hammani, Roukaya Benjelloun & Yassine Otheman. (2021) Major depressive disorder: Validated treatments and future challenges. World Journal of Clinical Cases 9:31, pages 9350-9367.
Crossref
Crossref
Grzegorz Ślifirski, Marek Król & Jadwiga Turło. (2021) 5-HT Receptors and the Development of New Antidepressants. International Journal of Molecular Sciences 22:16, pages 9015.
Crossref
Crossref
Sagar Karia, Avinash De Sousa & Ruksheda Syeda. (2021) A “Real-World” Chart Review Study of Monotherapy and Adjunctive Vortioxetine in Clinical Practice. Indian Journal of Private Psychiatry 14:2, pages 92-94.
Crossref
Crossref
Mir Hilal Ahmad, M. Moshahid Alam Rizvi, Mahino Fatima & Amal Chandra Mondal. 2021. The Neuroscience of Depression. The Neuroscience of Depression
341
350
.
Nagarjuna Chary Ragi, Ganga Reddy Velma, Pavan Kumar Pallerla, Sana Siddiqua, Veeresham Alugonda, Hari Krishna Reddy Rachamalla, Srihari Pabbaraja & Prabhakar Sripadi. (2020) Identification and characterization of forced degradation products of vortioxetine by LC/MS/MS and NMR. Journal of Pharmaceutical and Biomedical Analysis 188, pages 113442.
Crossref
Crossref
Firouzeh Borhannejad, Behnam Shariati, Sina Naderi, Mohammadreza Shalbafan, Amirhosein Mortezaei, Erfan Sahebolzamani, Atefe Saeb, Seyyed Hosein Mortazavi, Leila Kamalzadeh, Ali Aqamolaei, Ahmad Ali Noorbala, Alireza Namazi‐Shabestari & Shahin Akhondzadeh. (2020) Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics 45:4, pages 804-811.
Crossref
Crossref
Qingqing Cheng, Jihan Huang, Ling Xu, Yunfei Li, Huafang Li, Yifeng Shen, Qingshan Zheng & Lujin Li. (2020) Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression. International Journal of Neuropsychopharmacology 23:2, pages 76-87.
Crossref
Crossref
Jocelien D. A. Olivier & Berend Olivier. (2019) Antidepressants and Sexual Dysfunctions: a Translational Perspective. Current Sexual Health Reports 11:3, pages 156-166.
Crossref
Crossref
Tarek Zghoul, Philip J. Cowen & Catherine J. Harmer. 2019. The Serotonin System. The Serotonin System
95
104
.
Jay J. Patel, Dale W. Smith, John Heafner, Christopher NG & George T. Grossberg. 2019. Primary Care Mental Health in Older People. Primary Care Mental Health in Older People
85
109
.
Alyssa M. Peckham, Austin De La Cruz & Robert L. Dufresne. (2018) Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?. Mental Health Clinician 8:4, pages 175-183.
Crossref
Crossref
Gernot Wagner, Marie-Therese Schultes, Viktoria Titscher, Birgit Teufer, Irma Klerings & Gerald Gartlehner. (2018) Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. Journal of Affective Disorders 228, pages 1-12.
Crossref
Crossref
Pratap R. Chokka & Jeffrey R. Hankey. (2017) Assessment and management of sexual dysfunction in the context of depression. Therapeutic Advances in Psychopharmacology 8:1, pages 13-23.
Crossref
Crossref
Hairong He, Wei Wang, Jun Lyu, Jie Zheng, Liyang Guo, Xiaofang An, Yajuan Fan & Xiancang Ma. (2018) Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. Journal of Psychiatric Research 96, pages 247-259.
Crossref
Crossref
Dee Lochmann & Tara Richardson. 2019. Antidepressants. Antidepressants
135
144
.
Alaeddine Djillani, Mariel Pietri, Sébastien Moreno, Catherine Heurteaux, Jean Mazella & Marc Borsotto. (2017) Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Frontiers in Pharmacology 8.
Crossref
Crossref
An Kang, Tong Xie, Dong Zhu, Jinjun Shan, Liuqing Di & Xiao Zheng. (2017) Suppressive Effect of Ginsenoside Rg3 against Lipopolysaccharide-Induced Depression-Like Behavior and Neuroinflammation in Mice. Journal of Agricultural and Food Chemistry 65:32, pages 6861-6869.
Crossref
Crossref
Jocelien D.A. Olivier, Diana C. Esquivel Franco, Marcel D. Waldinger & Berend Olivier. 2017. Sexual Dysfunction. Sexual Dysfunction.
Catherine J Harmer, Ronald S Duman & Philip J Cowen. (2017) How do antidepressants work? New perspectives for refining future treatment approaches. The Lancet Psychiatry 4:5, pages 409-418.
Crossref
Crossref
Daniel J. Safer. (2016) Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants. Journal of Clinical Psychopharmacology 36:5, pages 483-491.
Crossref
Crossref
Lin Song, Yao Liu, Fang Liu, Ruoqi Zhang, Huanhuan Ji & Yuntao Jia. (2016) Vilazodone for major depressive disorder in adults. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Rebecca L Andersen, Daniel J Johnson & Jai N Patel. (2016) Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways. Pharmacogenomics 17:4, pages 417-434.
Crossref
Crossref
Stephan Köhler, Katharina Cierpinsky, Golo Kronenberg & Mazda Adli. (2016) The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. Journal of Psychopharmacology 30:1, pages 13-22.
Crossref
Crossref
Cecilio Álamo, Francisco López-Muñoz & Pilar García-García. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
445
463
.
Carlos H. Rojas-Fernandez. 2016. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
29
48
.
William James Deardorff & George T. Grossberg. (2015) The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Current Geriatrics Reports 4:4, pages 301-311.
Crossref
Crossref
Angel L. Montejo, Laura Montejo & Felipe Navarro-Cremades. (2015) Sexual side-effects of antidepressant and antipsychotic drugs. Current Opinion in Psychiatry 28:6, pages 418-423.
Crossref
Crossref
Weifeng Mi, Fude Yang, Huafang Li, Xiufeng Xu, Lehua Li, Qingrong Tan, Guoqiang Wang, Kerang Zhang, Feng Tian, Jiong Luo, Jielai Xia, Kai Yuan, Lin Lu, Jiahui Deng, Jingwei Tian & Hongyan Zhang. (2021) Efficacy, Safety, and Tolerability of Ansofaxine (Ly03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo Controlled, Dose-Finding, Phase 2 Clinical Trial. SSRN Electronic Journal.
Crossref
Crossref